US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

STF Tactical Growth ETF

34.92

+0.32350.93%

Post-market: 34.86-0.0635-0.18%16:04 EDT

Volume:10.01K

Turnover:347.61K

Market Cap:192.08M

PE:- -

High:34.92

Open:34.71

Low:34.41

Close:34.60

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TUG"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TUG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TUG\",,,,,undefined,":{"symbol":"TUG","market":"US","secType":"STK","nameCN":"STF Tactical Growth ETF","latestPrice":34.9235,"timestamp":1750708800000,"preClose":34.6,"halted":0,"volume":10009,"hourTrading":{"tag":"盘后","latestPrice":34.86,"preClose":34.9235,"latestTime":"16:04 EDT","volume":3,"amount":104.7705,"timestamp":1750709057082},"delay":0,"floatShares":5500000,"shares":5500000,"eps":0,"marketStatus":"Closed","change":0.3235,"latestTime":"06-23 16:00:00 EDT","open":34.71,"high":34.9235,"low":34.41,"amount":347606.9152,"amplitude":0.014841,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750752000000},"marketStatusCode":5,"adr":0,"listingDate":1652932800000,"exchange":"NASDAQ","adjPreClose":34.6,"sharesOutstanding":5500000,"nav":34.61,"aum":190355000,"dividendRate":0.047532,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.86,"preClose":34.9235,"latestTime":"16:04 EDT","volume":3,"amount":104.7705,"timestamp":1750709057082},"volumeRatio":0.373003},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TUG\",,,,,undefined,":{"symbol":"TUG","floatShares":5500000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.373003,"shares":5500000,"dividePrice":1.66,"high":34.9235,"amplitude":0.014841,"preClose":34.6,"low":34.41,"week52Low":27.14,"pbRate":"--","week52High":36.83,"institutionHeld":0,"latestPrice":34.9235,"eps":0,"divideRate":0.047532,"volume":10009,"delay":0,"ttmEps":0,"open":34.71,"prevYearClose":33.52,"prevWeekClose":34.6,"prevMonthClose":34.28,"prevQuarterClose":30.96,"fiveDayClose":34.5453,"twentyDayClose":33.7,"sixtyDayClose":31.94},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TUG\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TUG\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526550996","title":"Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2526550996","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526550996?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:35","pubTimestamp":1744284900,"startTime":"0","endTime":"0","summary":"– Clinically Meaningful Efficacy Observed on Multiple Assessments –。– Confirmed Target Engagement with Reduced Iron Signal in MSA Affected Brain Regions –。Type: Oral Presentation Title: Topline Data from a Randomized, Double Blind, Placebo Controlled Phase 2 Study of ATH434 in Multiple System AtrophyPresenter: Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical CenterSummary: The oral presentation produced additional data on Alterity’s ATH434-201 Phase 2 clinical trial. Overall, the study results support continued advancement of ATH434 for the treatment of MSA. The imaging outcomes in n=61 participants indicate a heterogeneous localization of pathology and evidence that ATH434 reduces the iron signal in MSA affected brain regions. The clinical analysis included 71 patients who had at least one-post baseline UMSARS I assessment. The data showed that on the modified UMSARS I rating scale, ATH434 demonstrated a clinically significant treatment effect versu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alterity-therapeutics-presents-encouraging-data-113500434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2125909759.SGD","TUG","AFG","LU1923622291.USD","LU0757428866.USD","BK4139","MSA","LU2211815571.USD","ATH.AU","BK4007","LU1815336091.USD","BK4117","BK4143","LU0053671581.USD","LU2125909916.SGD","LU0728928796.USD","ATHE","BK4178","BK4107","LENZ","AAN"],"gpt_icon":0},{"id":"2526317949","title":"Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2526317949","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526317949?lang=en_us&edition=fundamental","pubTime":"2025-04-10 03:20","pubTimestamp":1744226401,"startTime":"0","endTime":"0","summary":"Annexon, Inc. on Tuesday presented data for its late-stage targeted therapy, tanruprubart , for Guillain-Barré Syndrome .GBS is a neuromuscular emergency affecting at least 150,000 people worldwide yearly. The rare autoimmune disease is characterized by rapidly progressing and severe weakness that can lead to complete paralysis, often requiring intensive care and mechanical ventilation.Tanruprubart is a first-in-kind monoclonal antibody designed to block C1q, the initiating molecule of the classical complement cascade.In the Phase 3 pivotal trial of 241 patients, tanruprubart met the primary endpoint with consistent outcomes and rapid, more complete functional recovery versus placebo across multiple time points and clinical efficacy measures.Also Read: Mid-Cap Firm Annexon’s Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study. At Week 1, treated patients rapidly gained motor function and were 14-fold more likely to perform the Timed Up and Go  test, a standardized measur","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/annexons-investigational-drug-shows-rapid-192001266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TUG","BK4139","ANNX"],"gpt_icon":0},{"id":"2526840473","title":"Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2526840473","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526840473?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:05","pubTimestamp":1744142700,"startTime":"0","endTime":"0","summary":"Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS Disease Education C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057993/0/en/Annexon-Highlights-Pivotal-Data-on-First-Potential-Targeted-Therapy-for-Guillain-Barr%C3%A9-Syndrome-GBS-and-Showcases-New-GBS-Education-Campaign-at-American-Academy-of-Neurology-AAN-20.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","GBSG","TUG","ANNX","BK4139","AFG","AAN","BK4107","BK4178"],"gpt_icon":0},{"id":"2524940495","title":"Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524940495","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524940495?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:00","pubTimestamp":1743591600,"startTime":"0","endTime":"0","summary":"During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes  and Clinical Global Impression of Change . Neflamapimod was associated with a reduced incidence of falls in the Extension phase of the study and new data to be presented at AD/PD 2025 demonstrates improvements on endpoints measuring cognitive fluctuations and working memory. “The presentation of the Extension phase data at AD/PD 2025 is an opportunity to share our findings and engage deeply with the DLB medical community as we plan for pivotal development and work to bring neflamapimod to patients as rapidly as possible,” said John Alam, MD, Co-Principal Investigator of the RewinD-LB study and CEO of CervoMed. “The positive findings across the primary outcome measure and multiple additional clinically important endpoints evaluated in the first 16 weeks of the Extension phase strengthen our b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investigators-present-clinical-trial-results-110000131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRVO","LU0205193047.USD","CGIC","LU0205194284.USD","BK4139","LU0345774631.USD","LU1169590202.USD","LU0240878834.USD","LU1169589451.USD","BK4097","DLB","LU0345774391.USD","LU0348723411.USD","LU0240877869.USD","PD","BK4023","TUG"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TUG\",params:#limit:5,,,undefined,":[{"date":"2025-03-26","symbol":"TUG","amount":0.01142,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-26","defaultRemindTime":1742995800000,"name":"STF Tactical Growth ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-27","payableDate":"2025-03-26","currency":"USD","dateTimestamp":1742961600000,"payDate":"2025-03-27"},{"date":"2024-12-26","symbol":"TUG","amount":1.60478,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-26","defaultRemindTime":1735223400000,"name":"STF Tactical Growth ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-26","currency":"USD","dateTimestamp":1735189200000,"payDate":"2024-12-27"},{"date":"2024-09-26","symbol":"TUG","amount":0.0261,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-26","defaultRemindTime":1727357400000,"name":"STF Tactical Growth ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-27","payableDate":"2024-09-26","currency":"USD","dateTimestamp":1727323200000,"payDate":"2024-09-27"},{"date":"2024-06-27","symbol":"TUG","amount":0.01787,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-27","defaultRemindTime":1719495000000,"name":"STF Tactical Growth ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-27","currency":"USD","dateTimestamp":1719460800000,"payDate":"2024-06-28"},{"date":"2024-03-20","symbol":"TUG","amount":0.016096,"announcedDate":"2024-03-19","type":"dividend","market":"US","newRecordDate":"2024-03-21","defaultRemindTime":1710941400000,"name":"STF Tactical Growth ETF","recordDate":"2024-03-22","payableDate":"2024-03-21","currency":"USD","dateTimestamp":1710907200000,"payDate":"2024-03-22"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TUG\",market:\"US\",,,undefined,":[{"executeDate":"2022-06-22","recordDate":"2022-06-23","paymentDate":"2022-06-24","value":0.009806,"currency":"USD"},{"executeDate":"2022-09-21","recordDate":"2022-09-22","paymentDate":"2022-09-23","value":0.093,"currency":"USD"},{"executeDate":"2022-12-21","recordDate":"2022-12-22","paymentDate":"2022-12-23","value":0.142894,"currency":"USD"},{"executeDate":"2023-03-22","recordDate":"2023-03-23","paymentDate":"2023-03-24","value":0.2006,"currency":"USD"},{"executeDate":"2023-06-21","recordDate":"2023-06-22","paymentDate":"2023-06-23","value":0.038356,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TUG\",market:\"US\",delay:false,,,undefined,":{}}}